GMP

REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Revance Stockholders and Encourages Investors to Contact the Firm

Saturday, October 16, 2021 - 2:00am

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Revance Therapeutics, Inc. (Revance or the Company) (NASDAQ: RVNC) on behalf of Revance stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Revance Therapeutics, Inc. (Revance or the Company) (NASDAQ: RVNC) on behalf of Revance stockholders.
  • Our investigation concerns whether Revance has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Click here to participate in the action.
  • On October 12, 2021, the U.S. Food and Drug Administration (FDA) posted Form 483 to its website citing issues found during the inspection of a Revance facility in July 2021.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Friday, October 15, 2021 - 2:23pm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Revance Therapeutics, Inc. (Revance or the Company) (NASDAQ: RVNC ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Revance Therapeutics, Inc. (Revance or the Company) (NASDAQ: RVNC ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • Revance is the subject of an FDA Form 483 posted on October 12, 2021.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Scientific Solutions Is Proud To Continue Working With TruSteel To Bring Cutting Edge Equipment To The Cannabis/Hemp Space

Friday, October 15, 2021 - 1:45pm

Because of Operation Warp Speed, TruSteel is proud to announce the launch of a new product series: The AutoVap 40 GMP.

Key Points: 
  • Because of Operation Warp Speed, TruSteel is proud to announce the launch of a new product series: The AutoVap 40 GMP.
  • Now, rotary evaporators and batch style evaporation processors can apply the pharmaceutical grade standard with a completely continuous process.
  • We also offer installs as well as servicing, support, and training on all the equipment we sell.
  • Celebrating its 4th year in business, TruSteel provides cutting-edge equipment, software, and solutions for pharmaceutical-grade botanical extraction and post-refinement.

Phase II Data Of Medigen COVID-19 Vaccine, Reviewed And Published In The Lancet Respiratory Medicine

Friday, October 15, 2021 - 11:19am

TAIPEI, Oct. 15, 2021 /PRNewswire/ -- The Lancet Respiratory Medicine , one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics (MVC) data from its MVC-COV1901 vaccine phase 2 clinical trial which demonstrates promising immunogenicity and safety profiles.

Key Points: 
  • TAIPEI, Oct. 15, 2021 /PRNewswire/ -- The Lancet Respiratory Medicine , one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics (MVC) data from its MVC-COV1901 vaccine phase 2 clinical trial which demonstrates promising immunogenicity and safety profiles.
  • Participants were administered intramuscularly two doses of either MVC-COV1901 or placebo 28 days apart.
  • In both younger and older adults who received the MVC-COV1901 vaccine, almost all participants had seroconversion in younger adults and 995% in older adults.
  • About Medigen Vaccine Biologics Corp. (MVC)
    MVC is a biopharmaceutical company using cell-based technologies to develop novel vaccines and biosimilars.

Phase II Data Of Medigen COVID-19 Vaccine, Reviewed And Published In The Lancet Respiratory Medicine

Friday, October 15, 2021 - 10:17am

TAIPEI, Oct. 15, 2021 /PRNewswire/ -- The Lancet Respiratory Medicine , one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics (MVC) data from its MVC-COV1901 vaccine phase 2 clinical trial which demonstrates promising immunogenicity and safety profiles.

Key Points: 
  • TAIPEI, Oct. 15, 2021 /PRNewswire/ -- The Lancet Respiratory Medicine , one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics (MVC) data from its MVC-COV1901 vaccine phase 2 clinical trial which demonstrates promising immunogenicity and safety profiles.
  • Participants were administered intramuscularly two doses of either MVC-COV1901 or placebo 28 days apart.
  • In both younger and older adults who received the MVC-COV1901 vaccine, almost all participants had seroconversion in younger adults and 995% in older adults.
  • About Medigen Vaccine Biologics Corp. (MVC)
    MVC is a biopharmaceutical company using cell-based technologies to develop novel vaccines and biosimilars.

Flerie Invest AB leads $52m acquisition of Swedish Biopharma Facility from Charles River

Friday, October 15, 2021 - 6:00am

Further investment and expansion of the facility and its current 128 employee roster is expected to begin immediately.

Key Points: 
  • Further investment and expansion of the facility and its current 128 employee roster is expected to begin immediately.
  • This acquisition is a major investment for us and fits well with Fleries strategy of investing in the gene and cell therapy space in Europe and the US, said Thomas Eldered, President of Flerie Invest.
  • Flerie Invest is a biotech and pharma investor managing a portfolio of more than 16 companies in Sweden, UK, US, the Netherlands, Iceland and Israel.
  • Flerie Invest, with offices in Stockholm and London, is an active member of SwedenBIO and the British Venture Capital Association (BVCA).

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Thursday, October 14, 2021 - 10:02pm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Revance Therapeutics, Inc. (Revance or the Company) (NASDAQ: RVNC ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Revance Therapeutics, Inc. (Revance or the Company) (NASDAQ: RVNC ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • Revance is the subject of an FDA Form 483 posted on October 12, 2021.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

RVNC BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation – RVNC

Thursday, October 14, 2021 - 8:59pm

The Rosen Law firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to http://www.rosenlegal.com/cases-register-2179.html or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

REVANCE THERAPEUTICS INVESTIGATION: Block & Leviton Is Investigating Revance Therapeutics, Inc. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Thursday, October 14, 2021 - 7:28pm

BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Revance Therapeutics, Inc. (NASDAQ: RVNC) for potential securities law violations.

Key Points: 
  • BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Revance Therapeutics, Inc. (NASDAQ: RVNC) for potential securities law violations.
  • Investors who have lost money in their Revance Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses.
  • Anyone who purchased Revance Therapeutics, Inc. stock and has lost money may be eligible, whether or not they have sold their investment.
  • Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.

Brain Wafers™ Offer Novel Path to Increase Neurotransmitters for Brain and Body Energy

Thursday, October 14, 2021 - 1:38pm

Offering on-the-go energy for brain and body, Brain Wafers have natural ingredients that enhance the body's own production of excitatory neurotransmitters safely increasing mental and physical energy, along with providing mood and memory support.

Key Points: 
  • Offering on-the-go energy for brain and body, Brain Wafers have natural ingredients that enhance the body's own production of excitatory neurotransmitters safely increasing mental and physical energy, along with providing mood and memory support.
  • Neurotransmitters are natural brain chemicals that help transmit nerve impulses to other nerves and organs, often classified as either stimulating or inhibiting.
  • Brain Wafers have natural precursors for aiding the body in creating these neurotransmitters.
  • Nutrients from Brain Wafers are quickly and efficiently absorbed and used, giving a needed energy lift that starts in minutes."